NeuroTech Newsletter #21
January 14, 2026
Executive Summary
Welcome to the 21st edition of the Carter Sciences Neurotech Newsletter!
As neurotechnology accelerates into 2026, investors are pouring over $150 million into innovative neuromodulation for sleep, asthma, and brain-computer interfaces, while the FDA's breakthrough designations and deregulatory push on AI wearables signal a fertile ground for rapid advancements in hearing diagnostics, ALS therapies, and automated brain fluid management. Clinical breakthroughs, from decoding pain in Parkinson's via neural signals to non-invasive ultrasound for rheumatoid arthritis and AI-enhanced deep brain stimulation, underscore a shift toward precision, non-invasive interventions, bolstered by strategic collaborations like Compass Pathways with Radial and spin-outs such as Lotus Neuro, alongside key leadership hires driving commercialization in cognitive health and neuromodulation—promising transformative impacts on neurodegenerative and chronic conditions.
Check out the highlights below and as always send through any recommendations or feedback to chay@cartersciences.com
Funding News
Neurosom Announces Oversubscribed Bridge Round Financing
Neurosom Press Release | 2026-01-12
Neurosom, the developer of a personalized, at-home neuromodulation therapy to improve deep and REM sleep as key factors in reducing dementia risk, announced the imminent closing of an oversubscribed bridge round of investment funding. CEO Viral Sheth expressed gratitude for the strong support of their Sleep WISP technology, which promises to reduce dementia risk, optimize sleep, and provide brain care for aging populations.
Spiro Medical Secures $67M Series A for Asthma Neuromodulation
PR Newswire | 2026-01-07
Spiro Medical, a company developing the first Pulmonary Neuromodulation System for asthma treatment, closed a $67 million Series A equity financing led by Andera Partners, Omega Funds, and Sherpa Healthcare Partners, with participation from HSG, Supernova Invest, and Northern Light Venture Capital.
Neurable Raises $35 Million Series A for BCI Technology
Yahoo Finance | 2025-12-19
Neurable, a leader in noninvasive brain-computer interface technology for everyday use, closed a $35 million Series A round to accelerate commercialization of Neurable AI, its patented brain-signal processing technology that integrates BCI into consumer devices, positioning cognitive health as the next major category in consumer tech.
MRC invests in experimental medicine dementia studies
UKRI | 2025-12-19
The Medical Research Council invested £16.5 million in five new studies on neurodegenerative diseases causing dementia, enabling researchers, patients, and industry partners to collaborate on understanding disease onset and progression, with the goal of identifying treatments to slow symptoms before they worsen.
NeuraWorx Closes Oversubscribed Seed Round Led by Nexus NeuroTech
Business Wire | 2025-12-18
Neuraworx Medical Technology, developing bioelectronic solutions for brain health originally from the University of Wisconsin-Madison, closed an oversubscribed Seed funding round led by Nexus NeuroTech Ventures, with participation from Foothill Ventures, Verge HealthTech Fund, Wisconsin Alumni Research Foundation, and other neurotech investors to advance neurotechnology therapy for CNS disorders.
Industry Analysis
These funding rounds, totaling over $150 million across private and public investments, highlight surging investor interest in neurotechnology applications spanning sleep optimization, asthma treatment, brain-computer interfaces, and dementia research, potentially driving faster innovation in noninvasive therapies and bioelectronics, while expanding market opportunities in cognitive health and neurodegenerative disease management for pharmaceutical and device companies.
Trend Conclusion
A clear trend emerges toward oversubscribed early-stage financings in neuromodulation and BCI technologies, particularly those targeting dementia risk reduction and CNS disorders, underscoring high confidence in neurotech's potential to address aging populations' brain health challenges through collaborative academic-industry models.
Regulatory & Reimbursement News
FDA Breakthrough Device Designation for Sofi Hearing Assessment System
MindAffect | 2026-01-12
The FDA has granted Breakthrough Device Designation to MindAffect's Sofi Hearing Assessment System, a rare honor awarded to only about 5% of medical devices annually and unprecedented for hearing diagnostics since the program's inception in 2015. This neurotechnology leverages brain-computer interface principles to enable objective hearing assessments, potentially accelerating development and market access for innovative diagnostic tools in auditory neurotechnology.
FDA Clears Empatica’s EmbraceMini for Sleep Monitoring
Empatica | 2026-01-08
Empatica's EmbraceMini wearable device has received 510(k) clearance from the FDA for sleep monitoring via actigraphy, addressing the need for reliable, patient-friendly solutions in clinical trials. This AI-enabled neurotechnology tool enhances scalable assessment of sleep patterns, supporting broader applications in neurological research and patient monitoring.
FDA announces sweeping changes to oversight of wearables, AI-enabled devices
STAT News | 2026-01-06
The FDA is easing regulations on digital health products, including AI-enabled wearables and neurodevices, in line with the Trump administration's deregulation agenda to promote innovation at "Silicon Valley speed." This shift prioritizes investor-friendly environments, potentially streamlining approvals while raising questions about safety oversight in the rapidly evolving neurotechnology sector.
FDA Clears BrainSpace Intellidrop for Automated Brain Fluid Management
PR Newswire / BrainSpace | 2026-01-02
BrainSpace's Intellidrop system has obtained 510(k) clearance from the FDA as an automated neurodevice for continuous brain pressure monitoring and precision drainage of brain fluid in ICU settings. This closed-loop technology tackles nursing shortages and generates AI training data, advancing automated interventions for neuro injury and degeneration.
PathMaker Neurosystems Receives FDA Breakthrough Device Designation for MyoRegulator in ALS
GlobeNewswire / PathMaker Neurosystems | 2025-12-17
PathMaker Neurosystems' MyoRegulator neuromodulation device has earned FDA Breakthrough Device Designation for non-invasive treatment to slow functional symptom progression in ALS patients. This designation facilitates expedited development and review for the clinical-stage neurotechnology, offering hope for improved management of neurodegenerative conditions.
Regulatory Impact Analysis
These FDA actions, including clearances for wearable sleep monitors and automated brain fluid systems alongside breakthrough designations for ALS neuromodulation and hearing assessments, signal accelerated innovation in neurotechnology. The broader deregulation of AI-enabled devices could reduce barriers to market entry, enabling faster deployment of tools that address clinical gaps like ICU staffing and neurological diagnostics, though it may necessitate industry vigilance on post-market safety to maintain trust in emerging technologies.
Regulatory Trend Conclusion
A clear trend toward expedited pathways and reduced oversight is evident, with multiple 510(k) clearances and breakthrough designations in early 2026 highlighting the FDA's support for AI-integrated neurodevices. This shift, coupled with policy changes favoring deregulation, positions the neurotechnology industry for rapid growth in wearables, neuromodulation, and automated systems, potentially transforming patient care in neurology while emphasizing the need for robust evidence generation amid lighter regulatory scrutiny.
Clinical News
ScienceDirect | 2026-01-12
This research study introduces a multivariable approach to decode endogenous pain levels in Parkinson's disease patients using wirelessly transmitted signals from the subthalamic nucleus, identifying specific frequency bands—gamma and beta in the contralateral STN, and delta and theta in the ipsilateral STN—as potential biomarkers for pain associated with the condition, offering new avenues for objective pain assessment in neuromodulation therapies.
Surf Therapeutics Announces Early Feasibility Study for Rheumatoid Arthritis Neuromodulation
BusinessWire | 2026-01-12
In this early feasibility clinical trial sponsored by Surf Therapeutics, a non-invasive ultrasound device is being evaluated to activate neural pathways for anti-inflammatory responses in rheumatoid arthritis patients, aiming to provide a drug-free alternative to traditional treatments by modulating neuro-immune interactions without surgery or implants.
BusinessWire | 2026-01-07
The completed PALOMA multicenter clinical trial, led by NeuraLight, represents one of the largest longitudinal studies utilizing eye-movement biomarkers to compare with standard clinical assessments in Parkinson's disease patients, advancing precision neurology by validating non-invasive biomarkers for disease monitoring and progression tracking.
Japanese scientists just built human brain circuits in the lab
ScienceDaily | 2026-01-07
This preclinical study by Japanese researchers developed miniature human brain circuits from fused stem-cell-derived organoids to observe real-time interactions between the thalamus and cortex, revealing the thalamus's critical role in cortical maturation and neural network organization through synchronized neuronal activity, which could inform neurotechnology designs for brain repair.
First-of-its-Kind Study Shows Visibility into Real-Time Spinal Cord Stimulation Utilization
Biotronik | 2026-01-05
This clinical study on the Prospera spinal cord stimulation system demonstrates the value of automatic daily remote monitoring for real-time insights into post-implant therapy adherence, identifying patterns of prolonged inactivity akin to "virtual explants" while showing sustained high usage rates, enhancing neuromodulation outcomes through objective utilization data.
Neurosurgery | 2025-12-05
In the phase 2 OPTIVIM clinical trial, the OptimDBS machine learning algorithm, trained on MRI data from patients with optimal deep brain stimulation outcomes for essential tremor, uses kernel ridge regression to compute precise stereotactic coordinates for asleep targeting, improving accuracy and efficacy in neuromodulation procedures for tremor control.
Clinical Impact Analysis
These developments in neurotechnology, spanning non-invasive neuromodulation for inflammatory conditions, biomarker-driven diagnostics for Parkinson's, and AI-enhanced deep brain stimulation targeting, promise to refine patient selection and therapy optimization in clinical practice, potentially reducing surgical risks, improving adherence through remote monitoring, and expanding access to personalized treatments for neurological disorders, ultimately enhancing quality of life and healthcare efficiency in the neurotechnology sector.
Research Trend Conclusion
A clear trend emerges toward integrating advanced biomarkers, machine learning, and non-invasive techniques in neurotechnology research, as evidenced by studies on neural signal decoding, eye-movement tracking, ultrasound neuromodulation, and organoid models, signaling a shift from invasive interventions to precision, real-time, and preclinical innovations that accelerate therapeutic development for movement disorders and chronic pain.
Commercial Collaborations and Launches
Compass Pathways Establishes Strategic Collaboration with Radial
Compass Pathways | 2026-01-06
Compass Pathways, a biotechnology firm focused on evidence-based innovations, has formed its seventh strategic collaboration with Radial Health, a network of interventional psychiatry practices. This partnership leverages Radial's technology and operations to enhance patient experiences and explore delivery models for COMP360, aiming to accelerate access to psychedelic-assisted therapies in mental health.
Thynk Inc Launches Skylar’s Run on Google Play
Thynk Inc | 2026-01-05
Thynk Inc has launched Skylar’s Run, a cognitive skill-building app, on Google Play for Android and Chrome devices. The application targets attention, focus, and self-regulation, integrating into school learning environments across Tier 1, Tier 2, and Tier 3 settings, with a focus on Chromebook users to broaden educational neurotech adoption.
BrainCheck Opens New York City Office to Support Northeast Growth
BrainCheck | 2026-01-05
BrainCheck, a digital cognitive assessment and care platform, has opened a new office at 325 Hudson Street in New York City to serve as its Northeast hub. This expansion targets rising demand from health systems, academic centers, specialty practices, and research organizations, strengthening regional commercial reach in cognitive health solutions.
Wearable Devices and Rokid Collaborate on Gesture Control for AR Glasses
Wearable Devices Ltd. | 2025-12-24
Wearable Devices Ltd., specializing in AI-powered touchless sensing, has partnered with Rokid, a leader in augmented reality and human-computer interaction. The collaboration integrates neural gesture control into AI and AR glasses, delivering natural, fast interactions for everyday use and advancing wearable neurotech interfaces.
Nexstim Advances Exclusivity with Sinaptica for Alzheimer's
Nexstim Plc | 2025-12-23
Nexstim Plc has progressed to the next phase of its exclusivity agreement with Sinaptica Therapeutics, finalizing payments to enable collaboration on Alzheimer's disease treatments. Building on the June 2025 agreement, this step advances neuromodulation technologies for neurodegenerative applications.
Soin Neuroscience and BIOTRONIK Neuro Announce Research Collaboration
Soin Neuroscience | 2025-12-19
Soin Neuroscience and BIOTRONIK Neuro have launched a research collaboration to refine personalized spinal cord stimulation using Soin's proprietary waveforms. Led by Dr. Amol Soin, the effort evaluates optimization methods to enhance neurostimulation outcomes in pain management.
Insightec Announces Spin-Out of Lotus Neuro
Insightec | 2025-12-17
Insightec has spun out Lotus Neuro, a clinical-stage biotech focused on focused ultrasound brain therapies, backed by Nexus NeuroTech Ventures. This move extends Insightec's platform to accelerate global development of non-invasive neurotreatments for neurological disorders.
Market Impact Analysis
These commercial developments signal heightened competition in neurotechnology by fostering cross-sector alliances that combine AI, wearables, and biotech expertise, potentially streamlining product commercialization and reducing entry barriers for innovative therapies. Expansions like BrainCheck's office opening and launches such as Skylar’s Run underscore strategic pushes into education and regional markets, driving revenue diversification and faster adoption amid growing demand for cognitive and mental health solutions, ultimately spurring industry-wide growth through integrated ecosystems.
Commercial Trend Conclusion
A clear trend emerges in strategic partnerships and spin-outs emphasizing AI integration, gesture-based interfaces, and targeted therapies for Alzheimer's and pain, reflecting a shift toward collaborative go-to-market strategies that prioritize personalization and scalability to address unmet needs in brain health and neuromodulation.
Leadership Appointments
Sevaro Appoints Carl Dugart as Chief Technology Officer
LinkedIn | 2026-01-07
Sevaro has appointed Carl Dugart as its new Chief Technology Officer. Dugart brings extensive experience in technology leadership, with a proven track record of building high-performing engineering teams, implementing scalable systems, and delivering innovative solutions for growth-oriented organizations. Most recently, he led transformative technology initiatives at Medically Home, focusing on enabling large-scale care delivery. This appointment signals Sevaro's push toward advanced neurotechnology infrastructure to support scalable innovation.
brain.space Hires Carmit S. as ML Researcher
LinkedIn | 2026-01-06
brain.space has welcomed Carmit S. as a new Machine Learning Researcher. Carmit brings more than 20 years of experience across leading tech organizations, including Google, and holds a PhD in Physics from Tel Aviv University. She spent the past 8.5 years at Aurora Labs, and her deep expertise will strengthen the Science team as the company advances cutting-edge research. This hire underscores brain.space's commitment to enhancing AI-driven neurotechnology research capabilities.
Cerevia Neurosciences Appoints Karen A. McGee as Board Chair
LinkedIn | 2025-12-29
Cerevia Neurosciences has appointed Karen A. McGee as Chair of its Board of Directors. McGee brings extensive experience in healthcare leadership and board governance, with a proven track record in guiding organizations through growth and regulatory milestones. Her strategic oversight is expected to support Cerevia's development efforts. This move positions Cerevia for stronger governance in navigating neurotech regulatory landscapes.
neo-bionica Appoints Andrew Csavoy as Senior Director of Business Development
LinkedIn | 2025-12-23
neo-bionica has appointed Andrew Csavoy as Senior Director of Business Development. Csavoy brings extensive experience in the market launch of neurostimulation therapies and implantable devices from his previous roles at Medtronic, St. Jude, and Abbott. His background also includes the introduction of novel therapies and stereotactic platforms acquired by these global corporations. This appointment aims to accelerate neo-bionica's commercialization of innovative neurostimulation solutions.
Brainreader Appoints Steve Green as Head of U.S. Sales
Brainreader | 2025-12-22
Brainreader, a leader in advanced neuroimaging and brain volumetrics, today announced the appointment of Steve Green as Head of U.S. Sales. In this role, Mr. Green will lead the company’s U.S. commercial strategy, oversee sales execution, and drive market expansion for Brainreader’s AI-driven brain volumetric solutions across health systems, academic medical centers, and strategic partners. This leadership addition is poised to boost Brainreader's penetration in the U.S. neuroimaging market.
Cadence Neuroscience Announces Medical Device Veteran Daniel Moore as Independent Board Director
Cadence Neuroscience | 2025-12-22
REDMOND, Wash., Dec 18, 2025 – Cadence Neuroscience, a medical device company advancing neuromodulation for personalized epilepsy care, today announced Daniel (Dan) Moore will be joining as Independent Board Director. Moore brings more than 35 years of leadership experience in the medical device industry, with a deep focus on epilepsy treatment and neuromodulation technologies. Moore currently serves as Chair of CMR Surgical, a U.K. This expertise will guide Cadence's strategic advancements in epilepsy neuromodulation.
Leadership Impact Analysis
These recent leadership appointments across neurotechnology firms highlight a strategic infusion of expertise in technology, research, sales, and governance, likely accelerating innovation in areas like AI-driven neuroimaging, neuromodulation, and neurostimulation therapies. Companies such as Sevaro and brain.space are bolstering technical capabilities to scale solutions, while sales and business development hires at Brainreader and neo-bionica signal aggressive market expansion, particularly in the U.S. Board enhancements at Cerevia and Cadence suggest a focus on regulatory navigation and growth oversight, potentially intensifying competition and fostering industry-wide advancements in personalized neurotech applications that could reshape market dynamics toward more integrated, patient-centric care models.
Executive Trend Conclusion
Emerging trends in neurotechnology leadership reveal a dual emphasis on deepening technical and R&D talent—evident in hires like CTOs and ML researchers—alongside commercial strengthening through sales and business development roles, reflecting companies' preparation for product launches and global scaling. The addition of seasoned board members with medtech and governance backgrounds indicates a maturing industry prioritizing strategic stability amid regulatory complexities, ultimately pointing to a shift toward interdisciplinary teams that blend AI, neuromodulation, and market savvy to drive sustainable innovation and adoption.
Closing Thoughts
Key Strategic Insights
This edition's neurotechnology landscape reveals a robust influx of over $150 million in funding for early-stage innovations in neuromodulation and brain-computer interfaces, targeting dementia prevention, asthma, CNS disorders, and consumer cognitive health, complemented by FDA's accelerated pathways including breakthrough designations for hearing diagnostics, ALS therapies, and AI-driven sleep monitoring, alongside clinical breakthroughs in biomarker decoding for Parkinson's pain and non-invasive ultrasound for rheumatoid arthritis; commercially, partnerships like Compass Pathways with Radial and spin-outs such as Insightec's Lotus Neuro underscore a pivot to scalable, personalized ecosystems, while leadership hires in AI research and sales signal maturation, collectively positioning the sector for explosive growth in addressing aging-related brain challenges through integrated, non-invasive solutions that blend biotech, wearables, and digital therapeutics.
Cross-Functional Analysis
Funding surges in sleep optimization and BCI technologies directly fuel regulatory advancements, as seen in FDA clearances for Empatica's EmbraceMini and BrainSpace's Intellidrop, enabling clinical trials like NeuraLight's Parkinson's biomarker study and Surf Therapeutics' anti-inflammatory neuromodulation to translate preclinical organoid insights into real-world applications; commercial expansions, from BrainCheck's regional hubs to Wearable Devices' AR integrations, leverage these clinical and regulatory tailwinds to form symbiotic alliances with established players like BIOTRONIK, while executive appointments in machine learning and business development at firms like brain.space and neo-bionica bridge R&D with market execution, creating a cohesive narrative of interdisciplinary convergence that mitigates risks in neurodegenerative and pain management pipelines, ultimately democratizing access to neurotech via AI-personalized, low-barrier interventions.
Future Outlook & Recommendations
As deregulation of AI wearables accelerates approvals and investor confidence propels oversubscribed rounds toward consumer BCI and preventive dementia tools, the industry is poised for a 2026 paradigm shift where non-invasive neuromodulation becomes mainstream, potentially capturing a $50 billion market in cognitive health by integrating with educational apps like Skylar’s Run and AR interfaces; executives should prioritize cross-sector collaborations to harness clinical data from trials like OPTIVIM for AI training, invest in U.S. sales infrastructure amid expansions like Brainreader's, and advocate for post-market surveillance amid lighter FDA oversight to ensure ethical scaling—recommend forming neurotech consortia for shared biomarker repositories and piloting hybrid psychedelic-neuromodulation models to outpace competitors in mental health and longevity markets.
Final Word
Neurotechnology's convergence of capital, clearance, and collaboration heralds an era of brain health empowerment, urging leaders to seize this momentum for transformative, patient-centric innovation.
© 2026 Carter Sciences. All rights reserved.
This newsletter is compiled for professionals in the Neurotechnology industry.
